Trial of Screening for ALOA-IgG AtheroAbzyme Test

Omicron Pharmaceuticals100 enrolled

Overview

This is a trial of screening for ALOA-IgG AtheroAbzyme Test comparing healthy, asymptomatic myocardial ischemic and acute coronary syndrome patients.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

100

Conditions

Myocardial Ischemia Acute Coronary Syndrome

Interventions

ALOA IgG-ElisaDEVICE

measurement of IgG Level in blood

ALOA IgG-AtheroAbzymeDEVICE

measurement of IgG in blood

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy patients * High Risk patients or Asymptomatic myocardial Ischemic patients * Acute Coronary Syndrome patients Exclusion Criteria: * None

Locations (1)

Bahman Hospital

Beirut, Haret Hriek, Lebanon

Outcomes

Primary Outcomes

Measuring the degree of oxidized low-density lipoprotein (LDL) by ALOA- IgG AtheroAbzyme in healthy and cardiovascular disease patients

Time frame: Three months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.